Project Grant R01TS000341

This $599,134 Project Grant award from the Agency for Toxic Substances and Disease Registry (ATSDR) under the State Capacity Building program (CFDA 93.240) supports a research study on ambient air pollution as a potential risk factor for amyotrophic lateral sclerosis (ALS). The study will take a multiomics approach within a high-quality epidemiologic investigation. The award was made to Karolinska Institutet, a prestigious medical research university in Sweden, to leverage its specialized...

This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...

This federal Project Grant award of $999,998.00 was provided by the Agency for Toxic Substances and Disease Registry (ATSDR) under the State Capacity Building program (CFDA 93.240). The grant aims to investigate persistent environmental toxicant exposures in the central nervous system (CNS) tissue of military veterans as potential etiological factors contributing to the development of amyotrophic lateral sclerosis (ALS). The primary awardee, Dartmouth-Hitchcock Clinic, will lead this research...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

This Project Grant award of $532,381.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The key objectives are to determine the gain-of-function effects of KIF5ADE27 in...

This Project Grant award of $558,182 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The primary objectives are to: 1) compare neurofilament species in ALS and control biofluids to identify ALS-specific neurofilament...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $374,349 to the University of North Carolina at Chapel Hill to develop and optimize a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research aims to establish a mouse model that accurately recapitulates the human disease...

The U.S. National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $1,059,110 Project Grant (CFDA 93.173) to the MGH Institute of Health Professions, Inc. to conduct a longitudinal study on social connectedness in individuals with amyotrophic lateral sclerosis (ALS). The study aims to identify the root causes of social disconnection in persons with speech-motor deficits due to ALS and develop targeted strategies to enhance social connectedness and mitigate the...

The University of North Carolina at Chapel Hill will use a $777,500 Project Grant from the Defense Health Agency to support research aimed at reducing expression of TDP-43 protein in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The grant was awarded on April 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through April 14, 2025, UNC-Chapel Hill researchers will investigate medical solutions for ALS at the project site in Chapel...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to investigate the effects of re-expressing embryonic motor neuron selector transcription factors ISL1 and LHX3 in postnatal motor neurons in mouse models of amyotrophic lateral sclerosis (ALS) and in induced pluripotent stem cell-derived ALS motor...